Member Info for trillsg

There will be news tomorrow.

There will be news tomorrow.

There will be news tomorrow.

There will be news tomorrow.

There will be news tomorrow.

There will be news tomorrow.

They haven't given away 51% of their technology kind sir. Testing, testing 123.

Can we agree some rules to avoid feeding narcissists?
1 Don't use their subject title
2 Try not to respond
3 If you must respond don't bite.
Btw many have broken this rule myself included!
"The first rule of Skin Trust Club is: You do not talk about Skin Trust Club."

T.Rat posts a lot of relevant and interesting stuff which I imagine takes hours to assemble. You merely vent your frustrations from investing in an associated company many moons ago.

Ok Muggins, this has become nonsensical now. Have a good evening.

Don't Helium count Muggins?

Which ever way you look Bronx the fact is that this huge company like what we have and want a piece of it.

Cheers bud.
Is this quote a leak?

This technology is currently being trialled in clinical centres across Europe, with results expected soon.

Hello our Swiss friends. Hope this helps.

Advantages of joining AIM
Guide
There are a number of benefits of joining AIM. The market can be a useful source of finance for business growth and can assist companies in raising their profile. Joining AIM can assist your company through providing:

access to a diverse range of investors - the opportunity to raise growth capital to enable your business to achieve its growth and innovation potential within a balanced regulatory environment
increased visibility and profile with key stakeholders, including customers and suppliers - which can aid access to global markets
access to a knowledgeable advisory community experienced in working with growing businesses
the ability to encourage employee commitment through offering share schemes to staff members
placing an objective value on the company's business
increasing the company's ability to make acquisitions, using quoted shares as currency
creating a market for the company's shares, helping to broaden the shareholder base
How is AIM a relevant source of finance for small and medium-sized companies?
If you are a smaller, growing business seeking finance for development and growth, AIM could be an appropriate source of finance for you. For example:

The AIM entry criteria are tailored to smaller, growing companies.
There is no prescriptive minimum entry size and/or trading history criteria.
Shareholder approval is only required for the most fundamental transactions - a reverse takeover or disposal resulting in a fundamental change of business.
Tax benefits - AIM shares have tax benefits for investors. Tax reliefs available can include inheritance tax and qualification for inclusion in Enterprise Investment Schemes and Venture Capital Trusts.
More appropriate costs - the costs of joining AIM may be more suitable for smaller companies than those that might be incurred by listing on the Main Market or obtaining debt finance such as a bank loan.
https://www.nibusinessinfo.co.uk/content/advantages-joining-aim#:~:text=Joining%20AIM%20can%20assist%20your,within%20a%20balanced%20regulatory%20environment

They sold 59 yesterday. Doesn't sound like many but if they did that, even at the lowest price plan, all year, they'd earn £6.4mill in revenue. Note, currently only available to iOS users and UK/IE and marketing hasn't kicked in yet.

I'd rephrase that bud, (Trillsg, the guy with too much time on his hands and access to Google) lol.

Posted this a bit back but more relevant after todays fantastic news. Chinese funded R&D ,
https://www.mdpi.com/2079-4991/11/4/991/htm

Abstract
Given the known presence of SARS-Cov-2 in wastewater, stemming disease spread in global regions where untreated effluent in the environment is common will experience additional pressure. Though development and preliminary trials of a vaccine against SARS-CoV-2 have been launched in several countries, rapid and effective alternative tools for the timely detection and remediation of SARS-CoV-2 in wastewater, especially in the developing countries, is of paramount importance. Here, we propose a promising, non-invasive technique for early prediction and targeted detection of SARS-CoV-2 to prevent current and future outbreaks. Thus, a combination of nanotechnology with wastewater-based epidemiology and artificial intelligence could be deployed for community-level wastewater virus detection and remediation.

I reckon the reduced price 'Special Offer' for STC is a clever move. If demand outstrips supply they can revert back to full price to slow it down also in the future they won't have the regret that they could have charged more. Something I was amazed to learn is that, Mobile Operating System Market Share Worldwide.....Android 71.81% V iOS 27.43% https://gs.statcounter.com/os-market-share/mobile/worldwide . So far we're only dealing 1/3 of the potential market and only the UK/IE with pretty much the rest of the world to follow.

jc, reading the RNS below it looks like it was at a 50% premium to what the sp was a month prior to the acquisition. I imagine the only disgruntled investors were the ones that didn't see it coming and only made 12% on the day prior to it been agreed. In 2008 the average acquisition premium was 21%.
https://www.investegate.co.uk/alltracel-pharm-plc--ap--/rns/offer-by-hemcom/200802221207425690O/
The Cash Consideration values the entire issued and to be issued share capital
of Alltracel at approximately £20.8 million.
The Cash Consideration represents a premium of approximately:

• 51.4 per cent. to 9.25 pence, being the Closing Price of an
Alltracel Share on 18 January 2008, being the last Business Day prior to the
commencement of the Offer Period;

• 12.0 per cent. to 12.50 pence, being the Closing Price of an
Alltracel Share on 21 February 2008, being the last Business Day prior to the
date of this announcement;

• 17.3 per cent. to 11.94 pence, being the average daily Closing Price
of an Alltracel Share during the 6 month period prior to the commencement of the
Offer Period; and

• 22.6 per cent. to 11.42 pence, being the average daily Closing Price
of an Alltracel Share during the 24 month period prior to the commencement of
the Offer Period.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/979870/S1192_Current_environmental_monitoring_cannot_constrainthe_effectof_vaccines_onSARS-CoV-2_transmission_Report_for_SAGE.pdf

Current environmental monitoring cannot constrain the effect of vaccines on
SARS-CoV-2 transmission: Report for SAGE 08/04/2021

Applications and future directions
While the current predictive ability of wastewater-based surveillance is promising, expanding these
models to include temporal structure and use information from multiple samples (such as distributed lag
models) is likely to increase the predictive performance. Explicitly modelling prediction errors will
continue to highlight areas of improvement for the EMHP wastewater surveillance programme. For
example, laboratory methods are being considered to lower the limit of quantification and detection and
new approaches to sample collection are being explored to reduce noise. Hierarchical modelling
approaches will facilitate integrating new sites into the national surveillance programme to expand the
population coverage of WBE and aid monitoring of public health beyond COVID-19. The value of
mechanistic (or process-based) modelling in supporting the study and management of environmentrelated health issues is increasingly recognised (Beltrame et al., 2021), and opportunities for using
mechanistic modelling in wastewater-based epidemiology are also being explored. Mechanistic modelling
could complement statistical models by providing a rationale for the nature of the relation between
prevalence and concentrations of the virus in wastewater. It could also help explain the noise in the data
over time, as well as variability between sites. Identifying where the data conflict with process-based
estimates could highlight opportunities for improving the collection and processing of data. Comparing
process-based estimates of prevalence from wastewater data under different assumptions
(vaccination/no vaccination, different NPIs) could be an alternative way of exploring the influence of these
interventions.
While WBE has been of limited use in assessing the impact of vaccines on SARS-CoV-2 transmission, the
EMHP programme has provided insight into areas of stubborn transmission, increasing prevalence of
SARS-CoV-2, community transmission of VOC/VUIs, and infection trends in settings including prisons and
schools. These insights have aided local and national teams in planning and responding to COVID-19, and
we will continue to expand on the operational use cases detailed in Wade et al., 2020 and Brown et al.,
2021 as WBE analytical capabilities and capacity develop further.